Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
EVGNREHOVOT, Israel, Aug. 28, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology and chemistry company, today announced that Ofer Haviv, Evogene's President and CEO, will present at the H.C. Wainwright 27th Annual Global Investment Conference, 2025,...
Evogene Reports Second Quarter 2025 Financial Results
EVGNConference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of...
Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases
EVGNA failure in metabolite breakdown leads to their ordered self-assembly into pathological aggregates, such as in Tyrosinemia and Gout. REHOVOT, Israel, Aug. 12, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company, today announced a...
Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud
EVGNLake Street Maintains Buy on Evogene, Lowers Price Target to $3.5
EVGNEvogene Q1 EPS $(0.38) Beats $(0.63) Estimate, Sales $2.44M Miss $4.42M Estimate
EVGNInsights into Evogene's Upcoming Earnings
EVGNICL To Acquire Majority Activity Of Evogene's Subsidiary Lavie Bio; Term Not Disclosed
EVGNDuring Q4 2024 And The Beginning Of 2025, Evogene Established An Expense Reduction Plan, To Better Align With Its Strategic Goals, Leading To A Reduction Of ~30% In Headcount, To Be Completed By The End Of Q1 2025
EVGNEvogene Q4 2024 GAAP EPS $0.06 May Not Be Comparable To $(0.72) Estimate, Sales $1.61M Miss $3.63M Estimate
EVGNAgPlenus Announces Discovery Of New Mode Of Action For Fungicides Against Wheat Disease
EVGNA Glimpse of Evogene's Earnings Potential
EVGNEvogene Subsidiary Lavie Bio's LAV321 Bio-Fungicide Advances To Pre-Commercial Stage After 70% Efficacy Against Downy Mildew In Grapes
EVGNEvogene shares are trading higher after the company announced a collaboration with Google Cloud to pioneer a generative AI foundation model for novel small molecule design.
EVGNEvogene Announces Collaboration With Google Cloud To Pioneer Generative AI Foundation Model For Novel Small Molecule Design, Leveraging Evogene's Deep Expertise In Computational Predictive Biology And Google Cloud's Leadership In AI And Machine Learning
EVGNAegis Capital Maintains Buy on Evogene, Lowers Price Target to $8
EVGN